4.4 Review

Antenatal screening for chromosomal abnormalities

期刊

ARCHIVES OF GYNECOLOGY AND OBSTETRICS
卷 305, 期 4, 页码 825-835

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00404-022-06477-5

关键词

Cell-free fetal DNA; Ultrasound; First trimester screening; Trisomy

资金

  1. Projekt DEAL

向作者/读者索取更多资源

Cell-free DNA analysis (cfDNA) is now the gold standard in screening for trisomy 21, but it does not cover all chromosomal disorders; in the first trimester, the optimal approach is to combine ultrasound assessment with cfDNA testing.
Screening for chromosomal disorders, especially for trisomy 21, has undergone a number of changes in the last 50 years. Today, cell-free DNA analysis (cfDNA) is the gold standard in screening for trisomy 21. Despite the advantages that cfDNA offers in screening for common trisomies, it must be recognized that it does not address many other chromosomal disorders and any of the structural fetal anomalies. In the first trimester, the optimal approach is to combine an ultrasound assessment of the fetus, which includes an NT measurement, with cfDNA testing. If fetal structural defects are detected or if the NT thickness is increased, an amniocentesis or a CVS with at least chromosomal microarray should be offered.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据